Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis

Journal of Cellular Biochemistry

Volumn 55, Issue 4, 1994, Pages 419-434

  Pepper, M S ^a   Vassalli, J D ^a   Orci, L ^a   Montesano, R ^a   Wilks, J W ^b   Schweigerer, L ^c  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b PFIZER INC   (United States)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

angiostatic steroids; heparin; interferon alpha 2a; plasminogen activator inhibitor 1; retinoic acid; suramin; urokinase type plasminogen activator

Indexed keywords

ALPHA2A INTERFERON; HEPARIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; RECOMBINANT ALPHA2A INTERFERON; RETINOIC ACID; STEROID; SURAMIN; U 24067; U 42129; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CATTLE; CONTROLLED STUDY; ENDOTHELIUM CELL; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ADRENAL CORTEX; ANIMAL; BETAMETHASONE; CATTLE; CELL DIVISION; CELLS, CULTURED; ENDOPEPTIDASES; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION; HEPARIN; HUMAN; INTERFERON ALFA-2A; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; SUPPORT, NON-U.S. GOV'T; SURAMIN; TRANSCRIPTION, GENETIC; TRETINOIN; URINARY PLASMINOGEN ACTIVATOR;

EID: 0028075088     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.240550403     Document Type: Article

References (102)

1. Interaction of heparin with plasminogen activators and plasminogen: Effects on the activation of plasminogen
2. Medroxyprogesterone acetate, an anti‐cancer and anti‐angiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells
3. Mast cell heparin stimulates migration of capillary endothelial cells in vitro
4. Binding of urokinase‐type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin
5. Mechanism of action of angiostatic steroids: Suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis
6. Modulation of endothelial cell shape and growth by retinoids
7. Inhibition of cell motility by interferon
8. Inhibition of human endothelial cell proliferation by heparin and steroids
9. Heparin potentiation of 3T3‐adipocyte stimulated angiogenesis: Mechanism of action on endothelial cells
10. Differentiation‐dependent stimulation of neovascularization and endothelial cell chemotaxis by 3T3 adipocytes
11. Suramin inhibition of growth factor receptor binding and mitogenecity in AKR‐2B cells
12. Centrosome reorientation in regenerating endothelial monolayers requires bFGF
13. Interferon‐α and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth
14. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment
15. Microvascular injury in pathogenesis of interferon‐induced necrosis of subcutaneous tumors in mice
16. Antiproliferative effects of suramin on androgen responsive tumor cells
17. Interferon alfa‐2a therapy for life‐threatening hemangiomas of infancy
18. Isolation and characterization of the human tissue‐type plasminogen activator structural gene including its 5′ flanking region
19. Basic fibroblast growth factor‐induced activation of latent transforming growth factor β in endothelial cells. Regulation of plasminogen activator activity
20. The extracellular regulation of growth factor action
21. Angiogenic factors
22. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone
23. Control of angiogenesis with synthetic heparin substitutes
24. Genistein, a dietary‐derived inhibitor of in vitro angiogenesis
25. 2‐methoxyestradiol, and endogenous estrogen metabolite, inhibits angiogenesis and suppresses tumor growth
26. Cultured endothelial cell monolayers that restrict the transendothelial passage of macromolecules and electrical current
27. Inhibition of angiogenesis by suramin
28. Effect of fibroblast growth factor and lipoproteins on the proliferation of andothelial cells derived from bovine adrenal cortex, brain cortex, and corpus luteum
29. Heparin protects basic and acidic FGF from inactivation
30. Inhibition of tumor growth, vascularization, and collagenolysis in the rabbit cornea by medroxy‐progesterone
31. Evaluation of the effect of suramin on neural cell growth and N‐CAM expression
32. The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events
33. Synergism of vitamins A and C on fibrinolysis
34. Inhibition of angiogenesis through modulation of collagen metabolism
35. A possible mechanism for inhibition of angiogenesis by angiostatic steroids: Induction of capillary basement membrane dissolution
36. Antiangiogenic effect of heparin and other sulphated glycosaminoglycans in the chick embryo chorioallantoic membrane
37. Regulators of angiogenesis
38. Sulfated polysaccharides modulate effects of acidic and basic fibroblast growth factors on repair on injured confluent human vascular endothelium
39. Synergism of retinoids and L‐ascorbic acid in producing plasminogen activator in endothelial cells
40. Mechanism of retinol‐induced activation of latent transforming growth factor‐β in bovine endothelial cells
41. The addition of endothelial cell growth factor and heparin to human umbilical vein endothelial cell cultures decreases plasminogen activator inhibitor‐1 expression
42. Stimulation of tissue‐type plasminogen activator synthesis by retinoids in cultured human endothelial cells and rat tissues in vivo
43. Bovine urokinase‐type plasminogen activator and its receptor: cloning and induction by retinoic acid
44. Suramin: Prototype of a new generation of antitumor compounds
45. Differential effects of interferon gamma and alpha on in vitro model of angiogenesis
46. Stimulation of tissue plasminogen activator production by retinoic acid: synergistic effect on protein kinase C‐mediated activation
47. Growth stimulation of bovine endothelial cells by vitamin A
48. Nature of the interaction of growth factors with suramin
49. Expression of urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor
50. In vitro angiogenesis on the human amniotic membrane: Requirements for basic fibroblast growth factor‐induced proteases
51. Tumor‐promoting phorbol esters induce angiogenesis in vitro
52. Increased proteolytic activity is responsible for the aberrant morphogenetic behaviour of endothelial cells expressing middle T oncogene
53. Phorbol ester induces cultured endothelial cells to invade a fibrin matrix in the presence of fibrinolytic inhibitors
54. Basic fibroblast growth factor induces angiogenesis in vitro
55. Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis and migration
56. Membrane and matrix localization of proteases: A common theme in tumor invasion and angiogenesis
57. Identification of an inhibitor of neovascularization from cartilage
58. Tumor necrosis factor induction of endothelial cell urokinase‐type plasminogen activator mediated proteolysis of extracellular matrix and its antagonism by γ‐interferon
59. Heparin enhances angiogenesis by a systemic mode of action
60. A highly potent antiangiogenic activity of retinoids
61. Epidermal growth factor receptor expression and suramin cytotoxicity in vitro
62. Treatment of hemangioendotheliomas with alpha interferon
63. Transforming growth factor beta‐1 modulates basic fibroblast growth factor‐induced proteolytic and angiogenic properties of endothelial cells in vitro
64. Proteolytic balance and capillary morphogenesis
65. Plasminogen activator inhibitor‐1 is induced in microvascular endothelial cells by a chondrocyte‐derived transforming growth factor‐beta
66. Upregulation of urokinase receptor expression on migrating endothelial cells
67. Urokinase‐type plasminogen activator is induced in migrating capillary endothelial cells
68. Biphasic effect of transforming growth factor‐β1 on in vitro angiogenesis
69. Suramin prevents neovascularization and tumor growth through blocking of basic fibroblast growth factor activity
70. The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells
71. Effects of exogenous heparin on the vasculogenesis of the chorioallantoic membrane
72. Modulation of endothelial cell growth induced by heparin
73. Heparin protects heparin‐binding growth factor‐1 from proteolytic inactivation in vitro
74. Effects of rIFN alpha, beta, and gamma on the morphology, proliferation, and cell surface antigen expression of human dermal microvascular endothelial cells
75. The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator in capillary endothelial cells
76. Endothelial cell‐derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation
77. Mechanism of the synergistic effect of heparin and cortisone against angiogenesis and tumor growth
78. Heparin plus cortisone acetate inhibit tumor growth by blocking endothelial cell proliferation
79. Autocrine activities of basic fibroblast growth factor: Regulation of endothelial cell movement, plasminogen activator synthesis and DNA synthesis
80. Interaction of endothelial cell growth factor with heparin: Characterization by receptor and antibody recognition
81. Vascularization induced in the cheek pouch of the syrian hamster by tumor and nontumor substances
82. Inhibition of angiogenesis by interferons: Effects on tumor‐ and lymphocyte‐induced vascular responses
83. Interaction of heparin with basic fibroblast growth factor: Protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan
84. Suramin: A novel antineoplastic agent with multiple potential mechanisms of action
85. Antitumor action of retinoids: Inhibition of tumor cell line‐induced angiogenesis and prevention of tumors in mice
86. Protamine is an inhibitor of angiogenesis
87. Effect on retinoic acid on the synthesis of tissue‐type plasminogen activator and plasminogen activator inhibitor‐1 in human endothelial cells
88. Human endothelial cells: Use of heparin in cloning and long‐term serial cultivation
89. Heparin‐steroid conjugates: New angiogenesis inhibitors with antitumor activity in mice
90. Inhibition of in vitro angiogenesis by lymphotoxin and interferon‐γ
91. Amiloride selectively inhibits the urokinase‐type plasminogen activator
92. Concomitant secretion of prourokinase and of a plasminogen activator‐specific inhibitor by cultured human monocytes‐macrophages
93. The plasminogen activator/plasmin system
94. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa‐2a
95. Treatment of childhood angiomatous diseases with recombinant interferon alfa‐2a
96. Steroid inhibitors of angiogenesis
97. Inhibition of angiogenesis with combination treatments of angiostatic steroids and suramin
98. Hyperthermia stimulates plasminogen activator inhibitor type 1 expression in human umbilical vein endothelial cells in vitro
99. 2 decreases the fibrinolytic potential of cultured bovine endothelial cells derived from pulmonary arteries and lung microvasculature
100. γ‐interferon counteracts interleukin‐1a stimulated expression of urokinase‐type plasminogen activator in human endothelial cells in vitro
101. Immunoradiometric quantitation of tissue plasminogen activator‐related antigen in human plasma: Crypticity phenomenon and relationship to plasma fibrinolysis
102. Angiogenesis State of the art